Use of ACE Inhibitors in Patients with Chronic Kidney Disease
Benefits of ACE Inhibitors in CKD
- The American Journal of Kidney Diseases and Annals of Internal Medicine recommend ACE inhibitors like petindopril for CKD patients with albuminuria (≥30 mg/g) as they slow the decline in kidney function beyond what would be expected from blood pressure reduction alone 1, 2
- For patients with diabetes, hypertension, and albuminuria, ACE inhibitors should be titrated to the maximum tolerated dose with close monitoring of serum potassium and creatinine, as recommended by the Annals of Internal Medicine 2
- ACE inhibitors may be considered in normotensive patients with CKD and albuminuria, as their renoprotective effect appears to be partly independent of blood pressure reduction, according to the American Journal of Kidney Diseases 1
- In patients with residual kidney function on dialysis, ACE inhibitors have been shown to preserve remaining kidney function, as reported by the American Journal of Kidney Diseases 1
Dosing and Monitoring Guidelines
- Monitor serum creatinine and potassium within 2-4 weeks after initiating therapy or changing dose, as recommended by the Annals of Internal Medicine 2
- An initial increase in serum creatinine up to 30% is expected and acceptable; this reflects hemodynamic changes and is usually not a reason to discontinue therapy, according to the Annals of Internal Medicine 2
Safety Considerations and Precautions
- Avoid combination therapy with other RAS blockers (ARBs or direct renin inhibitors) as this increases adverse effects without providing additional benefits, as recommended by the Annals of Internal Medicine and Praxis Medical Insights 2, 3
- Temporary reduction or holding of petindopril is recommended during periods of decreased oral intake, vomiting, or diarrhea to prevent acute kidney injury, according to Praxis Medical Insights 3